Gene Expression Profiling and Pathway Analysis of Superficial Bladder Cancer in Rats

Urology

Volumn 75, Issue 3, 2010, Pages 742-749

  Arum, Carl Jørgen ^a,b   Anderssen, Endre ^a   Tømmerås, Karin ^a   Lundgren, Steiner ^b   Chen, Duan ^a   Zhao, Chun Mei ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CALCIUM CHANNEL VOLTAGE DEPENDENT T TYPE ALPHA 1H SUBUNIT; CELL ADHESION MOLECULE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1C; DUAL OXIDASE 2; FICOLIN B; FOLLISTATIN; G PROTEIN COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER A; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUTATHIONE PEROXIDASE 2; HOMEOBOX B8; MATRILYSIN; MUCIN 4; MYXOVIRUS RESISTANCE 1; NEUROGLOBIN; NONSTRUCTURAL PROTEIN 5A TRANSACTIVATED PROTEIN 9; PHOSPHOGLYCERATE DEHYDROGENASE; PHOSPHOSERINE AMINOTRANSFERASE 1; PROTEIN; RAC GTPASE ACTIVATING PROTEIN 1; REGULATOR OF CALCINEURIN 2; RIBONUCLEOTIDE REDUCTASE M2; SCHLAFEN 3; T LYMPHOCYTE RECEPTOR; TETRASPANIN 1; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR GATA 5; TRANSGLUTAMINASE 1; UBIQUITIN CONJUGATING ENZYME E2C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; BIOINFORMATICS; BLADDER CANCER; CANCER CELL; CANCER MODEL; CANCER STAGING; CARCINOGENESIS; CARCINOMA IN SITU; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; HISTOLOGY; HOST; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNE SYSTEM; INOCULATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; FEMALE; GENE EXPRESSION PROFILING; RATS; RATS, INBRED F344; URINARY BLADDER NEOPLASMS;

EID: 77649193095     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.03.008     Document Type: Article

References (24)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Raghavan D., Quinn D., Skinner D.G., et al. Surgery and adjunctive chemotherapy for invasive bladder cancer. Surg Oncol 11 (2002) 55-63
3. Herr H.W., Donat S.M., and Reuter V.E. Management of low grade papillary bladder tumors. J Urol 178 (2007) 1201-1205
4. Sanchez-Carbayo M., and Cordon-Cardo C. Molecular alterations associated with bladder cancer progression. Semin Oncol 34 (2007) 75-84
5. Holmang S., Hedelin H., Anderstrom C., et al. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 153 (1995) 1823-1826
6. Herr H.W., and Morales A. History of bacillus Calmette-Guérin and bladder cancer: an immunotherapy success story. J Urol 179 (2008) 53-56
7. Liakou C.I., Narayanan S., Ng Tang D., et al. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun 7 (2007) 10-15
8. Dunn G.P., Bruce A.T., Ikeda H., et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3 (2002) 991-998
9. Yao R., Yi Y., Grubbs C.J., et al. Gene expression profiling of chemically induced rat bladder tumors. Neoplasia 9 (2007) 207-221
10. Dyrskjot L., Kruhoffer M., Thykjaer T., et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64 (2004) 4040-4048
11. Xiao Z., McCallum T.J., Brown K.M., et al. Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. Br J Cancer 81 (1999) 638-646
12. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder. Eur Urol 54 (2008) 303-314
13. Smyth G.K. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3 (2004) Article3
14. Reiner A., Yekutieli D., and Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19 (2003) 368-375
15. Ogata H., Goto S., Sato K., et al. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 28 (2000) 27-30
16. Kanehisa M., Araki M., Goto S., et al. KEGG for linking genomes to life and the environment. Nucleic Acids Res 36 (2008) D480-D484
17. van Houdt I.S., Sluijter B.J., Moesbergen L.M., et al. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int J Cancer 123 (2008) 609-615
18. Galon J., Costes A., Sanchez-Cabo F., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006) 1960-1964
19. Dunn G.P., Dunn I.F., and Curry W.T. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun 7 (2007) 12-28
20. Koebel C.M., Vermi W., Swann J.B., et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450 (2007) 903-907
21. Seifert P., Benedic M., and Effert P. Nerve fibers in tumors of the human urinary bladder. Virchows Arch 440 (2002) 291-297
22. Entschladen F., Lang K., Drell T.L., et al. Neurotransmitters are regulators for the migration of tumor cells and leukocytes. Cancer Immunol Immunother 51 (2002) 467-482
23. Lang K., Entschladen F., Weidt C., et al. Tumor immune escape mechanisms: impact of the neuroendocrine system. Cancer Immunol Immunother 55 (2006) 749-760
24. Saban M., O'Donnell M., Hurst R., et al. Molecular networks discriminating mouse bladder responses to intravesical bacillus Calmette-Guérin (BCG), LPS, and TNF-α. BMC Immunol 9 (2008) 4-24